Expressiona and Diagnostic Potential of miRNAs in NSCLC

Completed

• Conditions: Non Small Cell Lung Cancer
• Interventions: Other: No intervention

• Registration Number: NCT05815407
• Lead Sponsor: Al-Azhar University

Brief Summary

Its to explore the expression pattern, diagnostic and prognostic potentials of miRs (106b-5p, 601 and 760) in serum of NSCLC patients

Detailed Description

A retrospective observational study on NSCLC patients, to determine the serum expression levels if some miRNAs in NSCLC patients and to find if having proper diagnostic and prognostic values in early disease detection, and/or staging.

Study Timeline

• Study Start: 2018-09-01
• Primary Completion: 2022-09-30
• Study Completion: 2022-09-30
• Status Verified: 2023-04
• Study First Submitted: 2023-04-04
• Study First Submitted QC: 2023-04-04
• Last Update Submitted: 2023-04-04
• Study First Posted: 2023-04-18
• Last Update Posted: 2023-04-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• First time and recently diagnosed NSCLC patient

Exclusion Criteria

• Recurrent NSCLC
• Start of chemotherapy, radiotherapy or surgical intervention
• Previous treatment
• Cancer history

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Control subjects	No intervention	Appearantly healthy age-matched individuals
NSCLC patients	No intervention	Patients were diagnosed with NSCLC at any stage, then will be subdivided into Early stage, Lympho-node involvement stage and Distant metastatic stage

Primary Outcome Measures

Name	Time	Method
Determination of the expression	By the end of the study (September 2022)	Expression profiling of the selected miRNAs

Trial Locations

Locations (1)

Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt; 🇪🇬 Cairo, Egypt